Advanced Chemical Industries Limited

2nd Quarter ended Report 2022-2023 for the six months period ended on 31 December 2022

Advanced Chemical Industries Limited Statement of financial position Unaudited

		Fig	gures in '000' Taka
		As at	As at
	Note	31 December 2022	30 Junè 2022
Assets			
Property, plant and equipment	2	14,311,546	13,472,344
Right-of-use assets		669,514	392,249
Investments	3	2,739,283	3,267,746
Intangible assets		1,511	1,943
Biological assets		34,162	31,303
Deferred tax assets		207,246	47,611
Non-current assets		17,963,261	17,213,196
Inventories	4	7,598,342	7,187,025
Trade receivables	5	2,783,793	2,768,624
Other receivables		1,192,121	608,506
Inter-company receivables	6	29,284,471	26,285,592
Advances, deposits and prepayments	7	872,129	855,536
Cash and cash equivalents		997,511	794,546
Current assets	30000	42,728,366	38,499,829
Total assets		60,691,627	55,713,025
Equity			
Share capital		762,056	725,768
Share premium		402,310	402,310
Reserves		5,092,533	5,114,365
Retained earnings		15,128,643	14,426,633
Total equity		21,385,543	20,669,079
Liabilities			
Employee benefits	8	1,371,359	1,210,620
Long term borrowings	9	1,457,696	1,068,990
Non-current portion of lease liabilities		477,288	305,310
Non-current liabilities		3,306,342	2,584,920
Bank overdraft		4,776,319	3,357,929
Loans and borrowings	10	21,496,202	20,344,56
Current portion of lease liabilities		151,575	116,945
Trade payables		1,422,196	1,325,613
Inter-company payables	11	3,515,851	3,999,74
	12	3,639,668	2,834,92
Other payables Unclaimed/unpaid dividend account		444,979	82,81
Current tax liabilities		552,953	396,49
Current liabilities		35,999,742	32,459,02
Total liabilities		39,306,084	35,043,940
Total equity and liabilities		60,691,627	55,713,025
Companies Community Community (Community)		280.63	271.23

Managing Director

Director

Chief Financial Officer

Company Secretary

Advanced Chemical Industries Limited Statement of profit or loss Unaudited

	4.0			-	res in '000' Taka	
		For half y	ear from	For the 2nd o	uarter from	
		July 2022	July 2021	October 2022	October 2021	
		to	to	to	to	
	Note	December 2022	December 2021	December 2022	December 2021	
Revenue	13	14,651,284	14,828,347	7,808,504	7,189,359	
Cost of sales	14	(8,766,662)	(8,305,688)	(4,811,089)	(4,081,276)	
Gross profit		5,884,622	6,522,659	2,997,415	3,108,082	
Administrative, selling and distribution expenses	15	(5,094,072)	(4,820,531)	(2,566,025)	(2,401,072)	
Other income		611,549	466,111	510,062	436,866	
Operating profit		1,402,098	2,168,239	941,452	1,143,876	
Gain on disposal of investment in joint ventures and associates	18	249,078		249,078	W=-	
Net finance costs		(175,312)	(202,547)	(61,336)	(108,537)	
Profit before contribution to WPPF		1,475,864	1,965,692	1,129,194	1,035,338	
Contribution to WPPF		(73,793)	(98,285)	(56,460)	(51,767)	
Profit before tax		1,402,071	1,867,407	1,072,735	983,572	
Income tax expense		(300,891)	(477,393)	(178,368)	(238,257)	
Profit after tax	3	1,101,180	1,390,014	894,366	745,315	
Earnings per share						
Basic and diluted earnings per share (EPS) (in Taka)		14.45	18.24	11.74	9.78	

1 / JX

Managing Director

, James S. Salman

Director

Chief Financial Officer

Company Secretary

Advanced Chemical Industries Limited Statement of profit or loss and other comprehensive income Unaudited

	For half	year from	Figur For the 2nd	res in '000' Taka quarter from	
	July 2022 to December 2022	to to to		October 2021 to December 2021	
Profit after tax	1,101,180	1,390,014	894,366	745,315	
Other comprehensive income:					
Change in fair value of FVOCI financial assets	(24,258)	(51,455)	2,695	(26,953)	
Income tax on FVOCI financial assets	2,426	5,146	(269)	2,696	
Other comprehensive income, net of tax	(21,832)	(46,309)	2,426	(24,257)	
Total comprehensive income	1,079,348	1,343,705	896,793	721,058	

Advanced Chemical Industries Limited Statement of changes in equity Unaudited

						Figures i	n '000' Taka
				For th	e half year from	July 2022 to Dec	cember 2022
	Share capital	Share premium	Capital reserve	FVOCI reserve	Revaluation surplus	Retained earnings	Total equity
Balance at 1 July 2022	725,768	402,310	1,671	401,449	4,711,245	14,426,635	20,669,079
Total comprehensive income							
Profit after tax	-	-	-	-	-	1,101,180	1,101,180
Other comprehensive income, net of tax	-	-	-	(21,832)	-	-	(21,832)
Total comprehensive income	-	-	-	(21,832)	-	1,101,180	1,079,348
Transaction with owners of the Company							
Share premium	-	-	-	-	-	-	-
Stock dividend	36,288	-	-	-	-	(36,288)	-
Cash dividend	-	-	-	-	-	(362,884)	(362,884)
Total transactions with owners of the Company	36,288	-	-	-	-	(399,172)	(362,884)
Balance at 31 December 2022	762,056	402,310	1,671	379,618	4,711,245	15,128,643	21,385,543

				For the half year from July 2021 to December 202					
	Share capital	Share premium	Capital reserve	FVOCI reserve	Revaluation surplus	Retained earnings	Total equity		
Balance at 1 July 2021	631,103	402,310	1,671	453,052	4,711,245	12,693,655	18,893,035		
Total comprehensive income									
Profit after tax	-	-	-	-	-	1,390,014	1,390,014		
Other comprehensive income, net of tax	-	-	-	(46,309)	-	-	(46,309)		
Total comprehensive income	-	-	-	(46,309)	-	1,390,014	1,343,705		
Transaction with owners of the Company									
Share premium	-	-	-	-	-	-	-		
Stock dividend	94,665	-	-	-	-	(94,665)	-		
Cash dividend	-	-	-	-	-	(410,217)	(410,217)		
Total transactions with owners of the Company	94,665	-	-	-	-	(504,882)	(410,217)		
Balance at 31 December 2021	725,768	402,310	1,671	406,742	4,711,245	13,578,787	19,826,523		

Advanced Chemical Industries Limited Statement of cash flows Unaudited

		Figures in '000' Taka
		year from
	July 2022	July 2021
	to December 2022	to December 2021
	December 2022	December 2021
Cash flows from operating activities		
Cash receipts from customers and others	14,783,243	14,638,073
Cash paid to suppliers and employees	(13,143,543)	(12,166,004)
Cash generated from / (used in) operating activities	1,639,700	2,472,069
Paid to WPPF	(11,488)	(11,473)
Finance costs paid	(151,173)	(197,483)
Income tax paid	(301,638)	(286,396)
	(464,299)	(495,352)
Net cash from / (used in) operating activities*	` ' '	1,976,717
Cash flows from investing activities	(156 105)	(77.225)
Acquisition of property, plant and equipment	(156,105)	(77,225)
Payments for capital work in progress	(922,428)	(334,333)
Sale proceeds from property, plant and equipment	703	2,713
Purchase of biological assets	(3,673)	(936)
Proceeds from disposal of investment in joint ventures and associates	583,107	(2.205)
Investment	64,000	(2,395)
Net cash from / (used in) investing activities	(434,397)	(412,177)
Cash flows from financing activities		
Inter-company debts received/(paid)	(3,417,001)	(5,181,213)
Dividend paid	(720)	(42,330)
Payment for lease liabilities	(81,398)	(91,251)
Short-term bank loan received/(paid)	1,011,819	1,343,962
Long-term bank loan received/(paid)	528,527	177,820
Net cash from / (used in) financing activities	(1,958,773)	(3,793,012)
Net increase / (decrease) in cash and cash equivalents	(1,217,769)	(2,228,472)
Opening cash and cash equivalents	(2,563,383)	(2,220,472) $(9,153)$
Effect of movements in exchange rates on cash held	2,344	8,256
Closing cash and cash equivalents	(3,778,808)	(2,229,370)
Closing balance represents		
Cash and cash equivalents	997,511	1,946,243
Bank overdraft	(4,776,319)	
Dank Overalall		(4,175,612)
	(3,778,808)	(2,229,370)

^{*}See Note 16 for reconciliation of net operating cash flow.

Advanced Chemical Industries Limited Consolidated statement of financial position Unaudited

	Unaudited	T.	gures in '000' Taka				
		As at	As at				
	Note	31 December 2022	30 June 2022				
Assets							
Property, plant and equipment	2 (a)	30,541,877	29,167,888				
Right-of-use assets		2,422,460	1,720,126				
Equity-accounted investees		1,681,430	2,157,944				
Other investments		854,774	822,290				
Intangible assets		1,362,500	1,354,161				
Biological assets		34,162	31,303				
Deferred tax assets		1,056,907	709,842				
Non-current assets		37,954,110	35,963,553				
Inventories	4 (a)	25,302,594	20,323,250				
Trade receivables	5 (a)	15,846,701	12,772,253				
Other receivables		1,277,786	832,501				
Inter-company receivables	6 (a)	960	5,613				
Advances, deposits and prepayments	7 (a)	4,122,916	2,512,498				
Current tax assets		4,430	103,392				
Cash and cash equivalents		2,862,974	3,208,757				
Current assets		49,418,361	39,758,264				
Total assets		87,372,472	75,721,817				
Equity							
Share capital		762,056	725,768				
Share premium		1,231,094	1,231,094				
Reserves		6,921,647	6,950,487				
Retained earnings		861,995	1,397,376				
Equity attributable to the owners of the Company		9,776,792	10,304,725				
Non-controlling interests		2,013,152	1,899,967				
Total equity		11,789,944	12,204,692				
Liabilities							
Employee benefits	8 (a)	1,795,594	1,583,157				
Long term borrowings	9 (a)	7,080,115	6,408,915				
Non-current portion of lease liabilities		1,924,420	1,384,718				
Non-current liabilities		10,800,130	9,376,790				
Bank overdraft		7,147,035	5,177,126				
Loans and borrowings	10 (a)	40,820,708	35,271,595				
Current portion of lease liabilities	10 (a)	402,867	382,471				
Trade payables		7,560,390	5,518,327				
Other payables	12 (a)	8,206,451	7,702,734				
Unclaimed/unpaid dividend account	12 (a)	644,947	88,082				
Current liabilities		64,782,398	54,140,334				
Total liabilities		75,582,528	63,517,125				
Total equity and liabilities		87,372,472	75,721,817				
Net asset value (NAV) per share (in Taka)	19	128.29	135.22				
	• /	120.27	100,22				

Managing Director

Director

1 menty

Chief Financial Officer

Company Secretary/

Advanced Chemical Industries Limited Consolidated statement of profit or loss Unaudited

				Figu	res in '000' Taka
		For half	year from	For the 2nd	quarter from
	Note	July 2022 to December 2022	July 2021 to December 2021	October 2022 to December 2022	October 2021 to December 2021
Revenue	13 (a)	57,064,982	45,818,649	30,280,936	24,264,977
Cost of sales	14 (a)	(43,940,994)	(33,631,673)	(23,271,170)	(18,007,460)
Gross profit		13,123,989	12,186,976	7,009,766	6,257,517
Administrative, selling and distribution expenses	15 (a)	(10,086,630)	(8,859,035)	(5,211,584)	(4,561,465)
Other income		244,329	157,159	47,179	81,884
Operating profit Share of profit of equity accounted investees Gain on disposal of investment in equity accounted investees.	18 (a)	3,281,687 74,241 416,029	3,485,101 214,349	1,845,361 32,055 416,029	1,777,935 134,405
Net finance costs		(2,419,221)	(1,832,473)	(1,241,706)	(947,931)
Profit before contribution to WPPF		1,352,736	1,866,977	1,051,738	964,409
Contribution to WPPF		(181,399)	(184,715)	(118,108)	(101,132)
Profit before tax		1,171,337	1,682,261	933,630	863,277
Income tax expense		(992,012)	(1,072,489)	(568,320)	(554,790)
Profit after tax		179,325	609,772	365,310	308,487
Profit attributable to:					
Equity holders of the company		(136,209)	400,235	149,596	152,082
Non-controlling interests		315,535	209,537	215,714	156,405
Profit after tax		179,325	609,772	365,310	308,487
Earnings per share					
Basic and diluted earnings per share (EPS) (in Taka)	19	(1.79)	5,25	1.96	2.00

Managing Director

Director

Chief Financial Officer

Advanced Chemical Industries Limited Consolidated statement of profit or loss and other comprehensive income Unaudited

	For half ye	ear from		res in '000' Taka quarter from
	July 2022 to December 2022	July 2021 to December 2021	October 2022 to December 2022	October 2021 to December 2021
Profit after tax	179,325	609,772	365,310	308,487
Other comprehensive income:				
Foreign operations - foreign currency translation differences	(12,022)	(23,034)	1,181	(18,231)
Change in fair value of FVOCI financial assets	(28,290)	(51,748)	(314)	(28,039)
Income tax on other comprehensive income	2,829	5,175	31	2,804
Other comprehensive income, net of tax	(37,482)	(69,607)	898	(43,466)
Total comprehensive income	141,843	540,165	366,208	265,021
Total comprehensive income attributable to:				
Equity holders of the Company				
Profit after tax	(136,209)	400,235	149,596	152,082
Other comprehensive income	(28,841)	(67,835)	3,281	(41,876)
	(165,050)	332,400	152,877	110,206
Non-controlling interest				
Profit after tax	315,535	209,537	215,714	156,405
Other comprehensive income	(8,642)	(1,772)	(2,382)	(1,590)
	306,893	207,764	213,331	154,815
Total comprehensive income	141,843	540,165	366,208	265,021

Advanced Chemical Industries Limited Consolidated Statement of changes in equity Unaudited

Figures in '000' Taka For the half year from July 2022 to December 2022

	Share capital	Share premium	Capital reserve	Translation reserve	FVOCI reserve	Revaluation reserve	Retained earnings	Total	Non-controlling Interests	Total equity
Balance at 1 July 2022	725,768	1,231,094	1,671	(80,757)	399,525	6,630,048	1,397,376	10,304,725	1,899,967	12,204,692
Total comprehensive income										
Profit after tax	-	-	-	-	-	-	(136,209)	(136,209)	315,535	179,325
Other comprehensive income - net of tax	-		-	(5,166)	(23,674)	-	-	(28,841)	(8,642)	(37,482)
Total comprehensive income	-	-	-	(5,166)	(23,674)	-	(136,209)	(165,050)	306,893	141,843
Transaction with owners of the Company										
Share premium	-	-	-	-	-	-	-	-	-	-
Stock dividend	36,288	-	-	-	-	-	(36,288)	-	-	-
Cash dividend	-	-	-	-	-	-	(362,884)	(362,884)	(194,707)	(557,591)
Capital contribution by non-controlling interest	-	-	-	-	-	-	-	-	1,000	1,000
Total transactions with owners of the Company	36,288	-	-	-	-	-	(399,172)	(362,884)	(193,707)	(556,591)
Balance at 31 December 2022	762,056	1,231,094	1,671	(85,923)	375,850	6,630,048	861,995	9,776,792	2,013,152	11,789,944

For the half year from July 2021 to December 2021

	Attributable to owners of the Company									
	Share capital	Share premium	Capital reserve	Translation reserve	FVOCI reserve	Revaluation surplus	Retained earnings	Total	Non-controlling Interests	Total equity
Balance at 1 July 2021	631,103	928,707	1,671	(1,397)	452,007	6,632,367	1,620,385	10,264,844	838,207	11,103,051
Total comprehensive income										
Profit after tax	-	-	-	-	-	-	400,235	400,235	209,537	609,772
Other comprehensive income - net of tax	-		-	(21,407)	(46,428)	-	-	(67,835)	(1,772)	(69,607)
Total comprehensive income	-	-	-	(21,407)	(46,428)	-	400,235	332,400	207,764	540,165
Transaction with owners of the Company										
Share premium	-	-	-	-	-	-	-	-	-	-
Stock dividend	94,665	-	-	-	-	-	(94,665)	-	-	-
Cash dividend	-	-	-	-	-	-	(410,217)	(410,217)	(62,802)	(473,018)
Effect of issuing new shares to Bangladesh Managed Account C.V. (a limited partnership of FMO) by ACI Motors Ltd.	-	254,217	-	-	10	(4,540)	(229,338)	20,348	648,826	669,173
Capital contribution by non-controlling interest	-	-	-	-	-	-	-	-	155,556	155,556
Total transactions with owners of the Company	94,665	254,217	-	-	10	(4,540)	(734,220)	(389,869)	741,579	351,711
Balance at 31 December 2021	725,768	1,182,924	1,671	(22,804)	405,589	6,627,827	1,286,400	10,207,375	1,787,551	11,994,926

Advanced Chemical Industries Limited Consolidated statement of cash flows Unaudited

	Figu	ıres in '000' Taka
	F	or half year from
	July 2022	July 2021
	to	to
	December 2022	December 2021
Cash flows from operating activities		
Cash receipts from customers and others	53,504,740	44,719,102
Cash paid to suppliers and employees	(56,598,868)	(41,803,118)
Cash generated from / (used in) operating activities	(3,094,128)	2,915,983
Paid to WPPF	(75,372)	(55,168)
Finance costs paid	(1,749,285)	(1,606,892)
Income tax paid	(1,205,232)	(847,071)
moone will pure	(3,029,889)	(2,509,132)
Net cash from / (used in) operating activities * 16 (a)	(6,124,017)	406,852
Cash flows from investing activities		
Acquisition of property, plant and equipment	(271,080)	(136,977)
Payments for capital work in progress	(1,905,522)	(621,552)
Sale proceeds from property, plant and equipment	2,703	2,713
Purchase of biological assets	(3,673)	(936)
Proceeds from disposal of investment in joint ventures and associates	583,107	-
Short term investments	-	(26,208)
Long term investments	(57,600)	(15,393)
Net cash from / (used in) investing activities	(1,652,066)	(798,353)
Cash flows from financing activities		
Inter-company debts received/(paid)	8,450	(108)
Dividend paid	(720)	(42,330)
Payment for lease liabilities	(179,942)	(228,211)
Dividend paid to non-controlling interest	(6)	(8,154)
Equity investment received by ACI Motors Limited	-	824,729
Short-term bank loan received/(paid)	3,239,216	(2,815,997)
Long-term bank loan received/(paid)	2,385,977	63,346
Net cash from / (used in) financing activities	5,452,976	(2,206,725)
Net increase / (decrease) in cash and cash equivalents	(2,323,107)	(2,598,226)
Cash and cash equivalents at 1 July	(1,968,368)	287,985
Effect of movements in exchange rates on cash held	7,414	9,124
Closing cash and cash equivalents	(4,284,062)	(2,301,118)
Closing balance represents		
Cash and cash equivalents	2,862,974	3,724,013
Bank overdraft	(7,147,035)	(6,025,131)
	(4,284,062)	(2,301,118)
Net operating cash flows per share (NOCFPS) (in Taka) 19	(80.36)	5.34

^{*}See Note 16(a) for reconciliation of consolidated net operating cash flow.

Advanced Chemical Industries Limited Notes to the financial statements as at and for the 2nd quarter ended on 31 December 2022 Unaudited

1 Selected explanatory notes

These financial statements have been prepared in line with Accounting Policies as adopted in the preparation of financial statements for the year ended from 1 July 2021 to 30 June 2022. This interim financial report includes only those selected explanatory notes as deemed appropriate for better understanding of unaudited financial statements.

		Figures in 1000 Taka						
2	Property, plant and equipment	31 December 2022	30 June 2022					
		<u> </u>	Taka					
	Opening balance	16,402,682	15,407,109					
	Additions and revaluation	1,078,533	1,009,436					
	Disposals and adjustments	(3,505)	(13,863)					
	Accumulated depreciation	(3,166,164)	(2,930,338)					
	Closing balance	14,311,546	13,472,344					
2 (a)	Consolidated property, plant and equipment							
	Opening balance	37,810,876	35,668,885					
	Additions and revaluation	2,159,977	2,179,879					
	Disposals and adjustments	(3,505)	(33,362)					
	Accumulated depreciation	(9,425,469)	(8,647,514)					
	Closing balance	30,541,877	29,167,888					
3	Investments							
	Investment in subsidiaries	1,751,736	1,751,736					
	Investment in joint ventures	185,000	510,000					
	Investment in associates	566,357	681,563					
	Investment in shares	504,252	527,510					
	Investment in FDR/ other deposits	5,538	70,538					
	Impairment	(273,600)	(273,600)					
		2,739,283	3,267,746					
4	Inventories							
	Raw materials	3,032,915	2,805,504					
	Packing materials	701,001	641,063					
	Work-in-process	390,156	384,174					
	Finished goods	3,950,090	3,269,607					
	Goods in transit	346,889	612,094					
	Stores and spares	99,901	93,268					
	Allowance for inventory	(922,610)	(618,685)					
		7,598,342	7,187,025					

		Fig	Figures in '000' Taka					
		31 December 2022	30 June 2022					
		Taka	Taka					
4 (a)	Consolidated inventories							
	Raw materials	8,685,193	6,819,248					
	Packing materials	862,263	733,206					
	Work-in-process	725,145	783,525					
	Finished goods	14,909,727	11,022,482					
	Goods in transit	1,118,241	1,478,350					
	Stores & spares	446,986	376,143					
	Allowance for inventory	(1,444,962)	(889,706)					
		25,302,594	20,323,250					
5	Trade receivables							
	Debts due over six months	1,709,878	1,885,401					
	Debts due below six months	1,786,069	1,586,756					
	Provision for doubtful debts	(712,154)	(703,533)					
		2,783,793	2,768,624					
5 (a)	Consolidated trade receivables							
	Debts due over six months	4,344,354	4,174,836					
	Debts due below six months	13,131,503	10,056,732					
	Provision for doubtful debts	(1,629,156)	(1,459,314)					
		15,846,701	12,772,253					
6	Inter-company receivables							
	ACI Logistics Limited	8,953,943	8,602,694					
	ACI HealthCare Limited	8,651,043	7,022,751					
	ACI Foods Limited	3,631,548	3,699,602					
	Premiaflex Plastics Limited	4,012,823	3,484,408					
	ACI Agrolink Limited	1,138,300	932,792					
	ACI Biotech Limited	1,028,631	963,401					
	ACI HealthCare USA Inc.	820,392	727,796					
	Infolytx Bangladesh Limited	674,183	610,649					
	ACI Chemicals Limited	243,291	232,071					
	ACI Motors Limited	104,022	-					
	ACI Edible Oils Limited	25,334	-					
	Asian Consumer Care (Pvt.) Limited	-	7,894					
	ACI Godrej Agrovet (Pvt.) Limited	930	930					
	Tetley ACI (Bangladesh) Limited	-	575					
	Computer Technology Limited	30	30					
		29,284,471	26,285,592					

		Fig 31 December 2022 Taka	igures in '000' Taka 30 June 2022 Taka	
6 (a)	Consolidated inter-company receivables			
	Computer Technology Limited Tetley ACI (Bangladesh) Limited	30	30 575	
	Asian Consumer Care (Pvt.) Limited	-	7,894	
	ACI Godrej Agrovet (Pvt.) Limited	930	930	
	Stochastic Logic Limited	930	(3,816)	
	Stochastic Logic Limited	960	5,613	
7	Advances, deposits & prepayments			
	Advances to staff, suppliers and others	250,093	241,100	
	VAT current account	114,076	197,537	
	Deposits	347,249	271,812	
	Prepayments	160,711	145,087	
		872,129	855,536	
7 (a)	Consolidated advances, deposits & prepayments			
	Advances to staff, suppliers and others	2,535,649	1,219,522	
	VAT current account	618,980	439,695	
	Deposits	483,210	523,608	
	Prepayments	485,077	329,673	
		4,122,916	2,512,498	
8	Employee benefits			
	Staff gratuity provision	1,076,846	950,030	
	Other long term employee benefits	294,513	260,590	
		1,371,359	1,210,620	
8 (a)	Consolidated employee benefits			
	Staff gratuity provision	1,400,595	1,232,845	
	Other long term employee benefits	394,999	350,312	
		1,795,594	1,583,157	

		31 December 2022 Taka	30 June 2022 Taka
9	Long term borrowings		
	Long term bank loans	1,457,696	1,068,990
	<u> </u>	1,457,696	1,068,990
9 (a)	Consolidated long term borrowings		
	Long term bank loans	7,080,115	6,408,915
		7,080,115	6,408,915
10	Loans and borrowings - short term		
	Short term loan	21,124,664	20,112,845
	Current portion of long term loan	371,538	231,717
		21,496,202	20,344,561
10 (a)	Consolidated loans and borrowings - short term		
	Short term loan	37,358,147	33,242,131
	Current portion of long term loan	3,462,560	2,029,464
	•	40,820,708	35,271,595
11	Inter company payables		
	ACI Marine and Riverine Technologies Limited	43,882	42,455
	ACI Motors Limited	-	934,628
	ACI Salt Limited	1,968,525	1,616,152
	ACI Pure Flour Limited	529,578	490,029
	ACI Edible Oils Limited	-	64,330
	Creative Communication Limited	57,939	62,811
	ACI Formulations Limited	915,927	785,527
	Stochastic Logic Limited	-	3,816

3,515,851

3,999,748

		31 December 2022 Taka	30 June 2022 Taka
12	Other payables		
	Accruals	1,955,669	1,307,201
	Advance from customers	11,857	23,915
	Security money received from customers	35,841	35,848
	Workers' profit participation fund	886,175	800,536
	Tax and VAT deducted at source	148,192	99,752
	Employees welfare fund	458,706	415,177
	Rights share deposit to be refunded	564	564
	Family day fund	6,261	5,880
	Non-management staff provident fund	7,978	6,021
	Unclaimed refund warrant - Zero Coupon Bonds	3,647	3,647
	Payable for redemption of Zero Coupon Bonds	20,403	20,403
	Management staff provident fund	10,830	26,599
	Advertisement and promotional funds	83,400	78,244
	Development funds	10,144	11,134
•	•	3,639,668	2,834,922
12 (a)	Consolidated other payables		
	Accruals	5,505,880	4,338,038
	Advance from customers	351,703	1,321,581
	Security money received from customers	101,667	98,065
	Workers' profit participation fund	1,281,146	1,141,424
	Management staff provident fund	10,830	26,599
	Tax and VAT deducted at source	364,121	235,630
	Employees welfare fund	458,706	415,177
	Rights share deposit to be refunded	564	564
	Family day fund	6,261	5,880
	Non-management staff provident fund	7,978	6,021
	Unclaimed refund warrant - Zero Coupon Bonds	3,647	3,647
	Payable for redemption of Zero Coupon Bonds	20,403	20,403
	Creditors for capital expenditure	· -	326
	Advertisement and promotional funds	83,400	78,244
	Development funds	10,144	11,134
•		8,206,451	7,702,734

		For half year from				
		July 2022 to December 2022 Taka	July 2021 to December 2021 Taka			
13	Revenue					
	Pharmaceuticals	6,901,349	7,379,417			
	Animal health	2,367,423	2,165,430			
	Consumer brands	3,458,626	3,429,397			
	Seeds	910,594	720,788			
	Fertilizer	831,452	1,008,272			
		181,840	125,043			
	Animal genetics	14,651,284	14,828,347			
		7 7 -	,			
13 (a)	Consolidated revenue					
	Gross sales	58,391,577	46,866,142			
	Inter-company sales	(1,326,595)	(1,047,492)			
		57,064,982	45,818,649			
14	Cost of sales					
	Opening stock	7,100,348	6,685,551			
	Purchase	8,250,940	7,372,388			
		15,351,288	14,057,939			
	Closing stock	(8,074,161)	(6,963,651)			
		7,277,127	7,094,288			
	Manufacturing expenses	1,489,535	1,211,400			
		8,766,662	8,305,688			
14 (a)	Consolidated cost of sales					
	Opening stock	19,364,928	16,031,441			
	Purchase	46,820,638	32,116,866			
		66,185,566	48,148,307			
	Closing stock	(25,188,795)	(17,010,482)			
		40,996,771	31,137,825			
	Manufacturing expenses	2,944,222	2,493,848			
		43,940,994	33,631,673			
15	Administrative, selling and distribution expenses					
	Administrative expenses	309,351	306,329			
	Distribution expenses	637,409	578,699			
	Selling expenses	4,147,311	3,935,503			
		5,094,072	4,820,531			

		For half year from			
	_	July 2022 to	July 2021 to		
		December 2022 Taka	December 2021 Taka		
15 (a)	Consolidated administrative, selling and distribution expenses				
	Administrative expenses	1,266,274	1,093,371		
	Distribution expenses	1,442,537	1,236,389		
	Selling expenses	7,377,819	6,529,274		
		10,086,630	8,859,035		
16	Reconciliation of net operating cash flow				
	Profit after tax	1,101,180	1,390,014		
	Adjustment for non-cash items and others:				
	- Gain on disposal of investment in joint ventures and associates	(249,078)	-		
	- Unrealized gain on translation of foreign currency receivables	(61,978)	-		
	- Depreciation and amoritisation	239,533	240,059		
	- Provisions	312,546	325,505		
	- Finance cost	175,312	202,547		
	- Tax expense	300,891	477,393		
	- Contribution to WPPF	73,793	98,285		
	-Lease and other adjustments	81,973	83,333		
	Changes in:				
	- Inventories	(715,242)	(256,226)		
	- Trade and other receivables	(501,227)	(805,446)		
	- Advances, deposits and prepayments	(88,289)	132,986		
	- Trade and other payables, employment benefits	970,287	583,618		
	Cash generated from operating activities	1,639,700	2,472,069		
	Paid to WPPF	(11,488)	(11,473)		
	Interest paid	(151,173)	(197,483)		
	Income tax paid	(301,638)	(286,396)		
	Net cash from operating activities	1,175,401	1,976,717		
16 (a)	Reconciliation of Consolidated net operating cash flow				
	Profit after tax	179,325	609,772		
	Adjustment for non-cash items and others:				
	- Gain on disposal of investment in equity accounted investees	(416,029)	-		
	- Depreciation and amoritisation	794,862	773,940		
	- Provisions	725,098	339,364		
	- Share of profit of equity accounted investees	(74,241)	(214,349)		
	- Finance cost	2,419,221	1,832,473		
	- Tax expense	992,012	1,072,489		
	- Contribution to WPPF	181,399	184,715		
	-Lease and other adjustments	179,942	228,211		

Changes in: - Inventories (5,534,601)(926,119)(1,429,435)- Trade and other receivables (3,322,223)- Advances, deposits and prepayments (1,685,319)161,447 - Trade and other payables, Employment benefits 2,466,426 283,475 Net cash from operating activities (3,094,128)2,915,983 Paid to WPPF (75,372)(55,168)Interest paid (1,749,285)(1,606,892)Income tax paid (1,205,232)(847,071)Net cash from operating activities (6,124,017)406,852

17 Consolidated operating segments

Please see Annexure A.

- Disposal of investment in joint ventures and associates
 - i) Advanced Chemical Industries Limited divested its entire shareholding in Asian Consumer Care (Pvt.) Limited at a consideration of Taka 600,000 thousand, for alignment with the future expansion plan of the Company (Advanced Chemical Industries Limited).
 - ii) Based on an amicable agreement with JV partner Tata Consumer Products Overseas Holdings Limited (TCP), Advanced Chemical Industries Limited divested its entire shareholding in Tetley ACI (Bangladesh) Limited at a consideration of Taka 106,177 thousand.

As a result of the disposal of the above investments, a gain of Taka 249,078 thousand has been recognized in the separate statement of profit or loss of the Company.

18 (a) Due to the disposal of the investments referred in Note 18, a gain of Taka 416,029 thousand has been recognized in the consolidated statement of profit or loss. These investments were earlier carried using equity method as per IAS 28 in the consolidated financial statements.

	For half year from				
	July 2022	July 2021			
	to	to			
	December 2022	December 2021			
Consolidated EPS, NAV per share, and NOCFPS					
Weighted average number of ordinary shares (in thousand)	76,206	76,206			
Consolidated profit attributable to equity					
holders of the Company (Taka '000)	(136,209)	400,235			
Earnings per share (Taka)	(1.79)	5.25			
Consolidated cash flows from operating activities (Taka '000)	(6,124,017)	406,852			
Net operating cash flows per share (NOCFPS)	(80.36)	5.34			
	31 December 2022	30 June 2022			
	Taka	Taka			
Consolidated net asset attributable to equity holders					
of the Company (Taka '000)	9,776,792	10,304,725			
Net asset value (NAV) per share	128.29	135.22			

19

Figures in '000' Taka

Reasons for significant deviations: During the six months period ended on 31 December 2022, the Group achieved a significant revenue growth which was mainly contributed by the sales growth in some of the business segments as demonstrated in Annexure-A: Consolidated operating segments. However, the increase in costs due to currency devaluation, hike in energy price, high import prices, and increased financing costs adversely affected overall profitiability of the Group. On the other hand, gain on disposal of investment in two equity accounted investees contributed to the group profit positively. The consequential result of decreased consolidated profit ultimately led to decrease in consolidated EPS. On the other hand, consolidated NOCFPS decreased mainly due to investment in working capital to facilitate business growth in the coming months.

Figures have been rounded off to the nearest '000' Taka and previous period's figures have been rearranged to conform to current period's presentation.

Annexure-A
Consolidated operating segments

Figures in '000' Taka For the half year from July 2022 to December 2022

	Reportable Segment											Total	Unallocated/	
Particulars	Pharmaceuticals	Animal	Consumer	Crop Care and	op Care and Motors	Pure Flour I	Retail Chain	l Chain Salt	alt Foods	Premiaflex	HealthCare	reportable	Elimination	Total
	Tharmaceuticals	Health	Brands	Public Health	Motors	Ture Piour	Retail Chain	Sait	10008	Treillianex	HealthCare	segments	Elilillation	
External revenue	6,901,349	2,367,423	3,340,052	2,185,006	14,466,984	4,385,495	8,405,178	1,540,635	4,789,999	3,502,620	1,234,611	53,119,353	3,945,629	57,064,982
Inter-segment revenue	-	-	419,370	-	49,709	78,738	13,200	17,339	73,713	420,619	125,592	1,198,281	128,313	1,326,595
Segment revenue	6,901,349	2,367,423	3,759,423	2,185,006	14,516,693	4,464,234	8,418,379	1,557,974	4,863,713	3,923,239	1,360,202	54,317,634	4,073,942	58,391,577
Depreciation and amortisation	155,044	12,504	44,130	9,522	40,938	19,407	70,537	42,514	33,619	135,818	181,349	745,382	49,480	794,862
Operating expenses	3,563,725	495,616	767,807	325,559	1,603,312	202,444	1,527,949	142,398	341,216	300,527	272,179	9,542,734	543,896	10,086,630
Finance cost / (income)	155,660	89,390	69,657	68,482	280,793	(15,101)	722,332	(47,830)	186,065	243,755	705,053	2,458,257	(39,036)	2,419,221
Segment profit/(loss) before tax	281,478	102,391	(121,533)	291,886	1,311,997	100,153	(669,065)	272,421	48,051	46,239	(1,199,107)	464,909	706,428	1,171,337
Segment assets at 31 Dec 2022	13,115,939	2,515,489	4,127,056	3,656,477	19,090,358	2,664,887	5,096,000	3,535,690	3,735,872	7,479,623	10,050,503	75,067,894	12,304,578	87,372,472
Segment liabilities at 31 Dec 2022	4,138,726	1,325,051	2,246,141	2,076,015	10,291,822	1,342,054	20,560,907	1,311,270	5,511,568	7,030,131	16,958,594	72,792,280	2,790,248	75,582,528

For the half year from July 2021 to December 2021

	Reportable segment											Total	Unallocated/	
Particulars	Pharmaceuticals	Animal Health	Consumer Brands	Crop Care and Public Health	Motors	Pure Flour	Retail Chain	Salt	Foods	Premiaflex	HealthCare	reportable segments	Elimination	Total
External revenue	7,379,417	2,165,430	3,271,994	1,834,765	9,824,856	2,807,162	6,412,997	1,404,936	3,571,465	3,078,356	810,629	42,562,005	3,256,644	45,818,649
Inter-segment revenue	-	-	411,436	-	14,344	47,561	36,948	21,468	74,582	313,339	-	919,678	127,815	1,047,492
Segment revenue	7,379,417	2,165,430	3,683,430	1,834,765	9,839,201	2,854,723	6,449,945	1,426,403	3,646,047	3,391,695	810,629	43,481,683	3,384,459	46,866,142
Depreciation and amortisation	150,616	13,302	47,785	8,964	37,856	19,209	76,694	34,906	32,618	134,151	175,952	732,052	41,888	773,940
Operating expenses	3,099,304	445,287	1,057,443	305,804	1,270,314	135,234	1,222,297	150,581	322,201	269,582	138,695	8,837,061	442,293	9,279,355
Finance cost / (income)	72,620	45,950	44,600	59,726	151,945	(21,306)	615,992	(43,132)	139,679	232,886	424,545	1,723,504	108,968	1,832,473
Segment profit/(loss) before tax	1,262,730	130,444	(154,720)	276,961	1,056,549	(7,437)	(581,143)	294,392	46,733	(69,486)	(865,742)	1,389,282	292,980	1,682,261
Segment assets at 30 June 2022	12,573,985	2,146,396	4,716,029	2,541,478	14,137,726	2,113,795	4,413,875	3,298,908	3,510,890	7,791,047	8,304,796	65,548,925	10,172,892	75,721,817
Segment liabilities at 30 June 2022	2,875,165	807,677	2,192,264	1,216,550	6,001,189	843,534	19,153,460	1,261,464	5,303,295	7,305,712	13,991,888	60,952,199	2,564,926	63,517,125